SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-071894
Filing Date
2021-05-25
Accepted
2021-05-25 17:10:25
Documents
12
Period of Report
2021-05-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2113070d2_8k.htm   iXBRL 8-K 26696
  Complete submission text file 0001104659-21-071894.txt   201543

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20210525.xsd EX-101.SCH 3184
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20210525_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20210525_pre.xml EX-101.PRE 22709
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2113070d2_8k_htm.xml XML 3636
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 21961639
SIC: 2834 Pharmaceutical Preparations